Nebraska Cancer Specialists

  • Home
  • Nebraska Cancer Specialists

Nebraska Cancer Specialists At Nebraska Cancer Specialists, we're committed to providing personalized cancer care close to home. Come Work with Us: NebraskaCancer.com/careers

Follow us for patient stories, health tips, treatment advances, community events, and the latest news. Our Locations

Midwest Cancer Center - Legacy
17201 Wright Street, Suite 200
Omaha, NE 68130

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250
Omaha, NE 68114

Henry Lynch Cancer Center - Bergan
7500 Mercy Road, Suite 1300
Omaha, NE 68124

Midwest Cancer Center - Papillion
611 Fenwi

ck Drive
Papillion, NE 68046

Methodist Fremont Health
405 East 23rd Street
Fremont, NE 68025

Think Whole Person Healthcare
7100 West Center Road
Omaha, NE 68106

Franciscan Care Services - West Point
430 North Monitor Street
West Point, NE 68788

Regional Cancer Center
2730 West Faidley Avenue
Grand Island, NE 68803

Hastings Landmark Center
2727 West 2nd Street Suite 314
Hastings, NE 68901

Mission Statement
To serve the community by providing personalized, comprehensive cancer care while respecting the values and needs of each patient. Company Information

Nebraska Cancer Specialists is a subspecialty practice of collaborating physicians who are devoted to oncology (tumors and cancer) and hematology (diseases of the blood and blood-forming organs). We are committed to providing you with state of the art medical treatment and compassionate care in our outpatient offices and hospital settings.

Catch Dr. Michalski LIVE on The Sit-In with Jack Swanda today from 4-5 p.m! See stations here:
03/09/2026

Catch Dr. Michalski LIVE on The Sit-In with Jack Swanda today from 4-5 p.m! See stations here:

31/08/2026

Hormones & Chemotherapy - how do we handle it? Dr. Wells explains!

A milestone in pancreatic cancer care.Yesterday, the FDA approved Rasonque™ (daraxonrasib), a groundbreaking new targete...
27/08/2026

A milestone in pancreatic cancer care.

Yesterday, the FDA approved Rasonque™ (daraxonrasib), a groundbreaking new targeted treatment for metastatic pancreatic cancer and the first approved therapy of its kind to target RAS, a key driver of this disease.

Earlier this summer, Nebraska Cancer Specialists became the first cancer center in Nebraska to provide eligible patients access to this promising therapy through the FDA’s Expanded Access Program before it received FDA approval.

For us, this moment represents more than a new treatment. It represents what is possible when innovation, research and personalized cancer care come together.

Thank you to the patients and families who put their trust in our physicians, research team and clinical staff whose expertise and commitment make it possible to bring promising new treatments to patients here at home.

The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.

26/08/2026
26/08/2026

Dr. Michalski, president and medical oncologist at NCS, says men should begin speaking with their primary care physicians about cancer screenings around age 40.

Thanks to Jim, the Legacy clinic always has beautiful, fresh flowers. 💐
24/08/2026

Thanks to Jim, the Legacy clinic always has beautiful, fresh flowers. 💐

21/08/2026

Kinda chic to be NCS!

Happy Medical Dosimetrist's Day! Our dosimetrists are vital members of our radiation oncology team.
19/08/2026

Happy Medical Dosimetrist's Day! Our dosimetrists are vital members of our radiation oncology team.

17/08/2026

Curious about how chemo may affect post-treatment pregnancy viability? Listen as Dr. Wells explains.

Address

NE

Alerts

Be the first to know and let us send you an email when Nebraska Cancer Specialists posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Want your business to be the top-listed Health & Beauty Business?

Share